Vitrolife

212 articles about Vitrolife

• Vitrolife AB (publ) announces changes in the Board of Directors

  8/1/2023

  According to plan and as previously announced, Henrik Blomquist will step down as Chairman of the Board of Vitrolife AB and the Board of Directors has appointed Jón Sigurdsson as the Chairman of the Board with effect from when Bronwyn Brophy assumes the position as CEO.

• Interim report Q2, 2023: Strong growth in APAC - Vitrolife AB (publ)

  7/14/2023

  Sales of SEK 905 (829) million, an increase of 9%, or 10% excluding discontinued business. In local currencies the growth was 3% and excluding discontinued business 4%.

• Vitrolife AB: Interim report Q1, 2023: Good start to the year

  4/21/2023

  In local currencies Consumables sales increased by 12%, Technologies 7% and Genetic Services excluding discontinued business by 7%.

• Vitrolife AB Fourth quarter and full year report 2022: Strong profitable growth

  2/2/2023

  Bronwyn Brophy is appointed as new CEO of Vitrolife AB (publ). She will join the company at the latest of 1 August 2023.

• Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)

  2/1/2023

  Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson.

• Vitrolife AB (publ): Conference call Year-end report, 2022

  1/20/2023

  Invitation to attend Vitrolife AB conference call regarding presentation of the Year-end report, 2022. The presentation will be held in English.

• Vitrolife´s CEO has purchased shares

  10/28/2022

  Vitrolife's CEO Thomas Axelsson has acquired 12,000 shares worth 2,124,000 MSEK.

• Vitrolife AB (publ) Interim report Q3, 2022: Actions done and synergies ahead

  10/27/2022

  Sales of SEK 798 (406) million, corresponding to an increase of 97% in SEK, whereof acquired growth 75% and currency effect 20%. Sales pro forma, adjusted for business related to Covid-19 tests, increased by 5% in local currencies.

• Vitrolife AB: Conference call interim report - October 18, 2022

  10/18/2022

  Invitation to attend Vitrolife AB conference call regarding presentation of the interim report January - September 2022.

• Vitrolife´s CEO to retire

  9/12/2022

  Thomas Axelsson, CEO of Vitrolife AB, informed the Board of Directors of his desire and intention to retire and be released from his position.

• Vitrolife AB (publ) Interim report Q2, 2022: Together for successful growth

  7/15/2022

  Vitrolife AB (publ) Interim report Q2, 2022: Together for successful growth.

• Vitrolife AB Interim report January-March 2022: Building on our strong growth momentum

  4/22/2022

  Consumables increased sales by 26% in SEK, Technologies by 4% in SEK, and Genetic Services contributed with sales of SEK 304 million.

• Notice of Annual General Meeting of Vitrolife AB (publ) - Mar 28, 2022

  3/28/2022

  Annual General Meeting of Vitrolife AB will take place on Wednesday 27 April 2022 at 4.00 pm at the Elite Park Avenue Hotel, Kungsportsavenyn 36-38 in Gothenburg, Sweden.

• Resolution on notice of Annual General Meeting of Vitrolife AB (publ)

  3/22/2022

  The Board of Directors has resolved that the Annual General Meeting of Vitrolife AB will take place on Wednesday 27 April 2022 at 4.00 pm.

• Report on Operations 2021: Continuous growth and a new Vitrolife

  2/16/2022

  Sales of SEK 514 (382) million, corresponding to an increase of 35 percent in SEK. Consumables increased by 9 percent, Genomics 33 percent, Technology decreased by 12 percent. The organic growth was 4 percent.

• Conference call Report on Operations 2021: Vitrolife AB (publ)

  2/3/2022

  Invitation to attend Vitrolife's conference call regarding presentation of the Report on Operations 2021.

• Vitrolife announces changes to the executive management team after the acquisition of Igenomix

  12/1/2021

  As announced on 30 November, 2021 , Vitrolife AB (publ) completed the acquisition of Igenomix, as a result, changes will be made to the executive management team effective 1 January, 2022.

• Vitrolife completes the acquisition of Igenomix and carries out a non-cash consideration issue

  11/30/2021

  Vitrolife AB entered into a definitive agreement to acquire 100% of the shares in Igenomix S.L.[1] from EQT and other shareholders.

• Vitrolife publishes prospectus in connection with the admission to trading on Nasdaq Stockholm due to non-cash issue

  11/26/2021

  Vitrolife AB publishes a prospectus for the admission to trading of newly issued shares in Vitrolife on Nasdaq Stockholm's main market in connection with a non-cash issue through which Vitrolife acquires all shares in Mendel Holdco S.L. and thereby indirectly all shares in Igenomix S.L.

• Interim report January - September 2021: Profitable growth and Igenomix acquisition

  10/29/2021

  Sales amounted to SEK 406 (320) million, corresponding to an increase of 27 percent in SEK. Sales increased by 30 percent in local currency.